-
Sep 2, 2024 | 
onlinelibrary.wiley.com | Julien Kirchgesner |Hôpital Saint-Antoine |Shirley Wang |Sebastian Schneeweiss
Corresponding Author Julien Kirchgesner Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA AP-HP, Hôpital Saint-Antoine, Department of Gastroenterology, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France Correspondence: Julien Kirchgesner ([email protected]) Sebastian Schneeweiss ([email protected]) Search for...
-
Aug 12, 2024 | 
acrjournals.onlinelibrary.wiley.com | Elvira D'Andrea |Pharmacoeconomics at Brigham |Sebastian Schneeweiss |Jessica Franklin
Supporting Information Filename Description art42968-sup-0001-Disclosureform.pdfPDF document, 420.8 KB Disclosure Form art42968-sup-0002-Supinfo.docxWord 2007 document , 11.6 MB Supporting Information S1
-
Aug 11, 2024 | 
acrjournals.onlinelibrary.wiley.com | Elvira D'Andrea |Sebastian Schneeweiss |Jessica Franklin |Seoyoung C. Kim
Supporting Information Filename Description art42968-sup-0001-Disclosureform.pdfPDF document, 420.8 KB Disclosure Form art42968-sup-0002-Supinfo.docxWord 2007 document , 11.6 MB Appendix S1: Supporting Information. REFERENCES 1, , , et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809–1822. 2, , , et al.
-
Jul 16, 2024 | 
dom-pubs.onlinelibrary.wiley.com | Karine Suissa |Sebastian Schneeweiss |Robert J Glynn |Deborah J. Wexler
Samy Suissa PhD Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada Department of Medicine, McGill University, Montréal, Quebec, CanadaSearch for more papers by this author
-
Jul 2, 2024 | 
ascpt.onlinelibrary.wiley.com | Sebastian Schneeweiss
CONFLICT OF INTEREST Dr. Schneeweiss is participating in investigator-initiated grants to the Brigham and Women's Hospital from Boehringer Ingelheim, Takeda, and UCB unrelated to the topic of this study. He owns equity in Aetion Inc., a software manufacturer. He is an advisor to Temedica GmbH, a patient-oriented data generation company. His interests were declared, reviewed, and approved by the Brigham and Women's Hospital in accordance with their institutional compliance policies.
-
May 8, 2024 | 
onlinelibrary.wiley.com | Shirley Wang |Kueiyu Joshua Lin |Sebastian Schneeweiss
CONFLICT OF INTEREST STATEMENT Dr. Schneeweiss is the principal investigator of the FDA Sentinel Innovation Center funded by the FDA, co-principal investigator of an investigator-initiated grant to the Brigham and Women's Hospital from Boehringer Ingelheim and UCB Pharma unrelated to the topic of this study. He is a consultant to Aetion Inc., a software manufacturer of which he owns equity.
-
Apr 8, 2024 | 
jamanetwork.com | Shirley Wang |Sebastian Schneeweiss
Many of the reasons why preregistration of randomized clinical trials (RCTs) has been embraced are also equally relevant for real-world evidence studies.1 The fear that preliminary looks at study results may motivate changes in study design is amplified in real-world evidence studies that use electronic health records or insurance claims. This is because data on the study end points are usually already collected at the time of study conception.
-
Apr 2, 2024 | 
onlinelibrary.wiley.com | Maria C. Schneeweiss |Arash Mostaghimi |Stephanie E Chiuve |Sebastian Schneeweiss
CONFLICT OF INTEREST STATEMENT Dr. Lin, Dr. Anand, Ms. Schoder, and Ms. Oduol have no financial disclosures to report. Dr. M. Schneeweiss has received a research grant to the Brigham and Women's Hospital from UCB pharma for work unrelated to the topic of this study. Dr. Mostaghimi reports personal fees from Pfizer, Digital Diagnostics, 3Derm, AbbVie, Bioniz, Concert, Lilly, Hims, and participation in clinical trials with Incyte, Aclaris, Concert, and Lilly outside the submitted work.
-
Feb 12, 2024 | 
jamanetwork.com | Sebastian Schneeweiss |Shirley Wang |Guneet Janda |Joshua D. Wallach
Hypothetical Assessments of Trial Emulations Feasibility of Emulating Trials Supporting Approvals of Drugs and Biologics Guneet S. Janda, BS; Joshua D. Wallach, PhD, MS; Meera M. Dhodapkar, BA; Reshma Ramachandran, MD, MPP, MHS; Joseph S. Ross, MD, MHS Hypothetical Assessments of Trial Emulations—Reply Guneet S. Janda, BS; Joshua D. Wallach, PhD, MS; Joseph S.
-
Feb 1, 2024 | 
bmjmedicine.bmj.com | Rachel Heyard |Leonhard Held |Sebastian Schneeweiss |Shirley Wang
Design differences and variation in results between randomised trials and non-randomised emulations: meta-analysis of RCT-DUPLICATE data Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
